AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...

Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

According to Lunit, patients identified by the AI model as having a high proportion of HER2 IHC 3+ tumour cells exhibited better clinical outcomes than those identified through traditional HER2 ...

Prediction of HER2 overexpression status and IHC score as seen in "Predicting the HER2 status in esophageal cancer from tissue microarrays using convolutional neural networks".